The Exchange has sought clarification from Zydus Lifesciences Limited with respect to recent news item captioned Lupin, Zydus Life shares fall up to 5% as US court sides with Astellas in Myrbetriq patent case. The response from the Company is attached.
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty 100 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zydus Lifesciences responded to stock exchange queries about a 5% fall in its share price. The US District Court for the District of Delaware issued an order on April 15, 2025, ruling against Zydus in a patent validity case filed by Astellas Pharma. The patent relates to the sustained-release formulation of mirabegron, marketed in the US as Myrbetriq. The company received the order only on the morning of April 16, 2025, and was preparing its SEBI-mandated disclosure within the required timeline. Zydus stated no negotiations were underway as this was a patent litigation matter. The company is now evaluating the order's impact on operations and the legal remedies available.
Negative for shareholders in the short term — the adverse US patent ruling restricts Zydus's ability to launch a generic version of Myrbetriq and may delay revenue from this product. The company has not quantified the financial impact yet, and the possibility of appeal or other legal remedies remains open, which could limit long-term damage.